文献速递药物不良反应与药物警戒

药物致性功能障碍:某国家药物警戒数据库报告分析

Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database.
PubMed 文献 · Drug Saf · 2022-04-07

共报告2815例性功能障碍不良反应,涉及722种药物/治疗组对;SSRIs、其他抗抑郁药和他汀类报告频率最高;男女不良反应类型存在差异,抗抑郁药、抗高血压药、口服避孕药、α受体阻滞剂和抗雄激素药报告数最多且比值比高。

要点

  • SSRIs、其他抗抑郁药和他汀类是性功能障碍报告最多的药物治疗组。
  • 男性以勃起功能障碍、性欲减退和射精障碍为主,女性以性欲障碍、性交痛和性功能障碍为主。
  • 抗抑郁药、抗高血压药、口服避孕药、α受体阻滞剂和抗雄激素药报告数多且比值比高。

核心结论

  • 不同性别之间检测到不同的性功能障碍不良反应及报告比值比差异。
  • 抗抑郁药、抗高血压药、口服避孕药、α受体阻滞剂和抗雄激素药是性功能障碍报告数最多且比值比高的药物治疗组。

研究设计与样本

  • 纳入至少包含一个MedDRA系统器官分类「生殖系统及乳腺疾病」和「精神疾病」中性功能障碍相关不良反应的报告,并按荷兰人群药物支出校正。

主要发现

  • 观察期间共报告2815例性功能障碍不良反应。
  • 共观察到722种不同的性功能障碍/药物治疗组对。
  • SSRIs报告488例(17.58%),其他抗抑郁药172例(6.20%),HMG-CoA还原酶抑制剂149例(5.37%)。
  • 男性更多报告勃起功能障碍、性欲减退和射精障碍,女性最常见性欲障碍、性交痛和性功能障碍。

关键数值与推荐

  • SSRIs为性功能障碍报告频率最高的药物治疗组(n=488,17.58%)。
  • 其他抗抑郁药报告n=172(6.20%),HMG-CoA还原酶抑制剂报告n=149(5.37%)。
  • 抗抑郁药、抗高血压药、口服避孕药、α受体阻滞剂和抗雄激素药报告数最多且比值比高。

临床怎么用

  • 临床用药时需关注抗抑郁药、抗高血压药、口服避孕药、α受体阻滞剂和抗雄激素药相关的性功能障碍风险。
  • 评估性功能障碍不良反应时应考虑性别差异,男性关注勃起和射精功能,女性关注性欲和性交痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sexual dysfunction (SD) is a problem that can affect any phase of the sexual response cycle (such as sexual desire, arousal and orgasm) and individuals of any age. SD can be caused by physical reasons, such as medical conditions, alcoholism or drug abuse; psychological factors, such as stress and anxiety; and different medicines, such as selective serotonin reuptake inhibitors (SSRIs), and their associated adverse effects. AIM: The aim of this study was to characterise drugs suspected to have caused SD adverse drug reactions (ADRs) in patients, by conducting a descriptive study based on pharmacovigilance reports. METHODS: Reports submitted to the Netherlands Pharmacovigilance Centre Lareb from January 2003 to December 2019 were used to investigate drug-induced sexual disorders. Selected reports had at least one ADR reported in the Medical Dictionary for Regulatory Activities (MedDRA®) System Organ Class (SOC) 'Reproductive system and breast disorders' and the SOC 'Psychiatric disorders' relating to sexual disorders and corrected for drug utilisation (expenditure) for the Dutch population. RESULTS: A total of 2815 SD ADRs were reported in the observed period. Data were divided according to three variables: pharmacotherapeutic group, the drug itself, and sex. A total of 722 different SD/pharmacotherapeutic group pairs were observed. The pharmacotherapeutic groups with the highest frequency of SD reports were SSRIs (n = 488, 17.58%), other antidepressants (n = 172, 6.20%) and HMG-CoA reductase inhibitors (n = 149, 5.37%). Distinguishing ADRs by sex, men suffered more from erectile dysfunction, decreased libido and ejaculation disorders, while among women, libido disorders, dyspareunia and SD were the most common ADRs. CONCLUSION: Different reactions and disproportionality of reactions were detected between the sexes. Antidepressants, antihypertensives, oral contraceptives, α-blockers, and anti-androgens were the pharmacotherapeutic groups with the highest number of SD reports and corresponding high odds ratios.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Valeiro C, Matos C, Scholl J, et al. Drug-Induced Sexual Dysfunction: An Analysis of Reports to a National Pharmacovigilance Database. Drug Saf. 2022. PMID: 35386045. doi:10.1007/s40264-022-01174-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。